On August 19, GENSCRIPT BIO rose 4.18% in regular trading, trading at 29.86 HKD/share, with turnover of HKD 359 million. The stock continued its post-earnings rally as multiple brokerages upgraded their outlooks.

On the news front, following the company's interim results released on August 16 that significantly beat expectations, Huatai Securities maintained a Buy rating with a target price of HKD 36.08, while CICC raised its target price by 78.8% to HKD 32.00, citing strong AIDD-driven life sciences business growth and improved operating efficiency.

The company reported H1 revenue of USD 404 million, up 27.3% year-over-year. The life sciences segment delivered adjusted operating profit of approximately USD 94 million, surging 102.8% YoY. AIDD-related business doubled year-over-year, maintaining rapid growth for three consecutive half-year periods. Adjusted net profit reached USD 62.5 million, up 203.3% YoY, driven by AI-powered drug discovery demand, CRDMO upstream recovery, and industrial enzyme expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)